It was quite positive, but about the small trials done at UCLA that used Poly-ICLC with DCVax-L, many patients living for ten or nearly ten years and still alive. The article wasn't being promoted by NWBO, or anyone else for that matter, as NWBO didn't sponsor the trial. IMHO NWBO's being heavily manipulate and will continue to be until the UK approval, then the news should overcome those working to control the share price. Their trial against the MM's for spoofing should be moving forward after multiple MTD's followed by more proof of the MM's actions.
Avanex should have no problem in PR'ing a Journal as they sponsored the trials being discussed in the Journal. Don't get me wrong, I'm sure if you attend ASCO they'll have copies of the article at their booth, but I know of no other formal presentation of the data discussed in the Journal there.
Gary
Bullish
News 
Market Data 
Discover 
